Indicated for the treatment of: 🧬 Hepatocellular Carcinoma (Liver Cancer): For patients with unresectable pathology. 🧬 Renal Cell Carcinoma (Kidney Cancer): For patients with advanced disease who have failed prior interferon-alpha or interleukin-2 based therapy. 🧬 Differentiated Thyroid Carcinoma: For progressive, radioactive iodine-refractory thyroid cancer.

Dosage and administration

Packaging: 200 mg film-coated tablets. ⚠️ ADMINISTRATION PROTOCOL: Standard Dose: 400 mg (2 tablets) taken twice daily. Total daily dose is 800 mg. Administration: Take without food (at least 1 hour before eating) or with a low-fat or moderate-fat meal. Do not take with high-fat meals. Swallow whole with water. Duration: Treatment continues as long as clinical benefit is observed or until unacceptable toxicity occurs.

Hypersensitivity to Sorafenib or any component of the formulation. Pregnancy and breastfeeding (can cause fetal harm). Severe cardiovascular events (e.g., recent myocardial infarction). Active bleeding or bleeding diathesis.

Common adverse reactions include: ✋ Dermatologic: Hand-foot skin reaction (redness, pain, swelling, or blisters on palms/soles), rash, alopecia. 🤢 Gastrointestinal: Diarrhea, nausea, vomiting. 📉 Cardiovascular/General: Hypertension (high blood pressure), fatigue, weight loss. Blood pressure should be monitored regularly during treatment.

Hepanib — Sorafenib 200 mg, 28 pcs, Everest

100% original product

Active ingredient

Sorafenib

Manufacturer

Everest

Dosage 200 mg

Dosage form Tablets

Tablets per pack 28

Hepanib (Sorafenib) Tablets

Name: Hepanib
Brand: Everest
SKU: PROD-134
Price: 1758 UAH
Availability: InStock

1758₴ ~~1978₴~~ -11%

Hepanib 200 mg (Sorafenib) is an oral multikinase inhibitor used for targeted cancer therapy.

Manufacturer: Everest Pharmaceuticals. Each pack contains 28 tablets. Sorafenib works by blocking signals that tell cancer cells to grow and by preventing the formation of new blood vessels that tumors need to survive (angiogenesis inhibition).

Clinical Value:

It is a first-line systemic therapy for patients with advanced liver cancer and advanced kidney cancer, helping to control disease progression.

Indicated for the treatment of:

🧬 Hepatocellular Carcinoma (Liver Cancer): For patients with unresectable pathology.
🧬 Renal Cell Carcinoma (Kidney Cancer): For patients with advanced disease who have failed prior interferon-alpha or interleukin-2 based therapy.
🧬 Differentiated Thyroid Carcinoma: For progressive, radioactive iodine-refractory thyroid cancer.

Packaging: 200 mg film-coated tablets.

⚠️ ADMINISTRATION PROTOCOL:

Standard Dose: 400 mg (2 tablets) taken twice daily. Total daily dose is 800 mg.
Administration: Take without food (at least 1 hour before eating) or with a low-fat or moderate-fat meal. Do not take with high-fat meals. Swallow whole with water.
Duration: Treatment continues as long as clinical benefit is observed or until unacceptable toxicity occurs.

Hypersensitivity to Sorafenib or any component of the formulation.
Pregnancy and breastfeeding (can cause fetal harm).
Severe cardiovascular events (e.g., recent myocardial infarction).
Active bleeding or bleeding diathesis.

Common adverse reactions include:

✋ Dermatologic: Hand-foot skin reaction (redness, pain, swelling, or blisters on palms/soles), rash, alopecia.
🤢 Gastrointestinal: Diarrhea, nausea, vomiting.
📉 Cardiovascular/General: Hypertension (high blood pressure), fatigue, weight loss.
Blood pressure should be monitored regularly during treatment.

Notice. The information on this page is for reference only and does not replace medical consultation. Always consult a healthcare professional and read the manufacturer's instructions before using any medicine. Self-medication may be dangerous. Information updated: 13.03.2026